中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

334 records (took 0.074 seconds)

    PROSTHETIC COMPOUNDS FOR LABELING INTERNALIZING BIOMOLECULES
    8.
    发明申请
    PROSTHETIC COMPOUNDS FOR LABELING INTERNALIZING BIOMOLECULES 审中-公开
    用于标记内在生物分子的前体化合物

    公开(公告)号：WO2014179715A1

    公开(公告)日：2014-11-06

    申请号：PCT/US2014/036615

    申请日：2014-05-02

    Applicant: DUKE UNIVERSITY

    Inventor： ZALUTSKY, Michael ,  VAIDYANATHAN, Ganesan

    IPC: A61K51/04 ,  A61K49/10 ,  A61K51/02 ,  A61K49/04

    CPC classification number: A61K51/1093 ,  A61K51/088 ,  A61K51/1051 ,  C07B59/002 ,  C07D207/416 ,  C07D207/46 ,  C07D403/12 ,  C07D487/04

    Abstract: Prosthetic compounds are disclosed that are effective for radiolabeling biomolecules with 18F. Representative biomolecules include antibodies (e.g., monoclonal antibodies (mAbs) and nanobodies (sdAbs)), antibody fragments, and peptides that may have an affinity for particular types of cells, such as cancer cells. The prosthetic compounds effectively address the art-recognized difficulties associated with the retention of radioactivity within the targeted cells, due to internalization of the biomolecule, followed by proteolytic degradation. Representative prosthetic compounds include (i) a succinimidyloxycarbonyl moiety, (ii) a radioactive moiety bearing 18F, and (iii) a charged moiety, i.e., a moiety that is charged under the physiological conditions of the internal cell environment.

    Abstract translation: 公开了具有18F放射性标记生物分子的假体化合物。 代表性的生物分子包括抗体（例如，单克隆抗体（mAb）和纳米抗体（sdAb）），抗体片段和可能对特定类型细胞如癌细胞具有亲和力的肽。 假体化合物由于生物分子内化，随后进行蛋白水解降解，有效地解决了与目标细胞内的放射性保留有关的技术上公认的困难。 代表性的假体化合物包括（i）琥珀酰亚胺氧基羰基部分，（ii）带有18F的放射性部分，和（iii）带电部分，即在内部细胞环境的生理条件下充电的部分。

    METHOD AND SYSTEM FOR TREATING A DISEASE USING COMBINED RADIOPHARMACEUTICALS
    9.
    发明申请
    METHOD AND SYSTEM FOR TREATING A DISEASE USING COMBINED RADIOPHARMACEUTICALS 审中-公开
    使用组合式放射性药物治疗疾病的方法和系统

    公开(公告)号：WO2014066798A3

    公开(公告)日：2014-06-26

    申请号：PCT/US2013066872

    申请日：2013-10-25

    Applicant: UNIV JOHNS HOPKINS

    Inventor： HOBBS ROBERT ,  SGOUROS GEORGE ,  WAHL RICHARD L

    IPC: G06Q10/00

    CPC classification number: A61K51/1069 ,  A61K51/1093 ,  G06F19/3481 ,  G06F19/704 ,  G06Q10/10 ,  G06Q50/24

    Abstract: A method and system of treating a disease for a patient, comprising assigning class data related to a class of patients that have characteristics similar to a specific patient and/or accessing patent data related to the specific patient; and optimizing a treatment plan, the optimizing being determined utilizing properties of a radiopharmaceutical used to treat the patient and the class data and/or the patient data.

    Abstract translation: 一种治疗患者疾病的方法和系统，包括：分配与具有与特定患者相似的特征的一类患者的类别数据和/或访问与特定患者有关的专利数据; 以及优化治疗计划，利用用于治疗患者的放射性药物的性质以及分类数据和/或患者数据来确定优化。

    RADIO-PHARMACEUTICAL COMPLEXES
    10.
    发明申请
    RADIO-PHARMACEUTICAL COMPLEXES 审中-公开
    放射性药物复合物

    公开(公告)号：WO2013167755A1

    公开(公告)日：2013-11-14

    申请号：PCT/EP2013/059840

    申请日：2013-05-13

    Applicant: ALGETA ASA

    Inventor： BONGE-HANSSEN, Hanne Therese ,  OLAV, Benjamin Ryan

    IPC: A61K51/04 ,  A61K51/10 ,  A61P35/00 ,  A61K103/40

    CPC classification number: A61K51/0474 ,  A61K51/0455 ,  A61K51/0478 ,  A61K51/1027 ,  A61K51/1093 ,  A61K2039/505 ,  C07K16/32 ,  C07K2317/24

    Abstract: A tissue-targeting complex comprising a tissue targeting moiety, an octadentate hydroxypyridinone-containing ligand comprising four HOPO moieties and the ion of an alpha-emitting thorium radionuclide, where at least one of the four HOPO moieties is substituted at the N-position with a hydroxyalkyi solubilising group and wherein the tissue targeting moiety has binding affinity for the CD33 receptor. A corresponding pharmaceutical formulation and method and use in treatment, as well as methods of manufacture are provided.

    Abstract translation: 包含组织靶向部分的组织靶向复合物，包含四个HOPO部分的八齿羟基吡啶酮配体和α发射钍放射性核素的离子，其中四个HOPO部分中的至少一个在N-位被取代为 羟基烷基增溶基团，其中组织靶向部分对CD33受体具有结合亲和力。 提供相应的药物制剂和方法以及在治疗中的用途以及制造方法。

Patent Agency Ranking